

Development of BK_{Ca} Channel Agonism Based New Drug Lead Compounds for Overactive Bladder Symptom

Gwangju Institute of Science & Technology



METABOLIC	Lead
Product Type	Small Molecules
Indication	Urinary Incontinence
Target	BK _{Ca} channel
MoA(Mechanism of Action)	Bladder relaxation by stabilizing open conformation of BKCa channel
Competitiveness	<ul style="list-style-type: none"> • Differing from conventional neuromuscular regulating medication, it is anticipated to have fewer side effects by promoting muscle relaxation directly through the opening of potassium channels in smooth muscle • low molecular weight novel drug with a molecular weight of 500 or less, and it exhibits excellent aqueous solubility and cell permeability
Development Stage	Lead
Route of Administration	Oral